memo - Magazine of European Medical Oncology
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
Practice changing data and new developments in the management of prostate cancer – ASCO 2010
memo - Magazine of European Medical Oncology - Tập 3 - Trang 164-166 - 2012
In the 2010 ASCO meeting valuable information and even practice-changing results
for the medical treatment of castration resistant prostate cancer (CRPC) were
presented. Focus was put on bone-targeted treatment, chemotherapy for second
line use, combinations of standard chemotherapy with different new drugs and
data on a novel antiangiogenic compounds. Denosumab was shown to be superior to
zoledro...
Therapy with JAK 1/2 inhibitors for myelofibrosis
memo - Magazine of European Medical Oncology - Tập 6 - Trang 109-113 - 2013
Myelofibrosis (MF) is currently the myeloproliferative disorder with the most
severe prognosis. A mutation of the JAK2 (V617F) enzyme is present in about 65 %
of patients. Inhibition of JAK-kinases was therefore a proposed treatment for
the disease. The purpose of this article is to give an updated overview about
the recent developments in the therapy of MF with JAK-inhibitors. We did a
research t...
Gastrointestinal cancers – still many questions to be resolved
memo - Magazine of European Medical Oncology - Tập 4 - Trang 61-61 - 2011
A GLOBAL CONGRESS DIGEST ON ON APPROACHES IN ADVANCED SOLID TUMORS. Report from the ESMO Immuno-Oncology Congress, 7th – 9th December 2022
memo - Magazine of European Medical Oncology - Tập 16 - Trang 53-64 - 2023
Results of children with renal tumors treated in the Austrian–Hungarian Wilms Tumor Study 1989 and the International Society of Pediatric Oncology (SIOP) 93-01/GPOH trial in Austria
memo - Magazine of European Medical Oncology - Tập 5 - Trang 289-295 - 2012
The overall outcome for children with nephroblastomas is excellent when treated
according to protocols that include surgery, chemotherapy, and, in selected
cases, radiotherapy. This study was conducted to provide population-based data
on Austrian children who had been treated in neoadjuvant nephroblastoma trials
between October 1988 and July 2001. One hundred and forty-eight children with
newly di...
Highlights in surgery of brain tumours
memo - Magazine of European Medical Oncology - Tập 3 - Trang 6-8 - 2010
The largest possible and safe removal of the lesion (also malignant) is the best
first step of treatment. The extra-axial benign lesions do require the best
possible surgical treatment, ideally a complete resection of the lesion without
endangering the surrounding neural and/or vascular structures. The most frequent
extra-axial intracranial tumours are: pituitary tumours, craniopharyngiomas,
centr...
The individualization of treatment based on molecular markers
memo - Magazine of European Medical Oncology - Tập 5 - Trang 251-252 - 2012
Recent developments have revealed various decisive discoveries in individualized
oncology for many different entities—the individualization of treatment based on
molecular markers representing just one of those milestones. The implication of
epidermal growth factor receptor (EGFR) mutations for EGFR-tyrosine kinase
inhibitor (TKI) treatment, the definition of the HER2 status in breast cancer
and t...
Immunotherapy in hepatocellular carcinoma
memo - Magazine of European Medical Oncology - Tập 13 - Trang 218-222 - 2020
Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver
cancers. The prognosis remains poor—the 5‑year overall-survival (OS) is 12–18%,
all stages taken together. Systemic therapy has been limited to the use of
tyrosine kinase inhibitors for more than a decade. Now immune therapy has also
arrived in the field of systemic HCC treatment. Despite initial enthusiasm, the
respons...
Cancer of unknown primary—state of the art
memo - Magazine of European Medical Oncology - - 2024
SummaryThe Cancer of Unknown Primary (CUP) syndrome does not represent a single
clinical entity but comprises a diverse group of malignant tumors. CUP is
defined as a histologically confirmed metastatic malignant disease for which the
primary tumor cannot be identified after completing initial diagnostics.
Although its incidence has decreased, managing CUP patients remains a
significant clinical c...
Open Access publizieren in „memo – magazine of european medical oncology“
memo - Magazine of European Medical Oncology - Tập 9 - Trang 1-1 - 2016
Tổng số: 854
- 1
- 2
- 3
- 4
- 5
- 6
- 10